BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mak A. T Cells, Interleukin-2 and Systemic Lupus Erythematosus—From Pathophysiology to Therapy. Cells 2022;11:980. [DOI: 10.3390/cells11060980] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Yan H, Yan H, Liu L, Su R, Gao C, Li X, Wang C. Low-dose interleukin-2 treatment increases the proportion of regulatory T cells in patients with rheumatic diseases: A meta-analysis. Autoimmun Rev 2023;22:103270. [PMID: 36627065 DOI: 10.1016/j.autrev.2023.103270] [Reference Citation Analysis]
2 Kotyla P, Gumkowska-sroka O, Wnuk B, Kotyla K. Jak Inhibitors for Treatment of Autoimmune Diseases: Lessons from Systemic Sclerosis and Systemic Lupus Erythematosus. Pharmaceuticals 2022;15:936. [DOI: 10.3390/ph15080936] [Reference Citation Analysis]